Lantern Pharma Inc.(LTRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LTRN Lantern Pharma Inc.

未开盘 05-26 16:00:00 EDT

3.38

-0.12

-3.43%

盘后3.31

-0.07-2.19%

19:03 EDT

最高3.70	最低3.34	成交量22.46万
今开3.53	昨收3.50	日振幅10.29%
总市值4,312万	流通市值3,408万	总股本1,276万
成交额78.85万	换手率2.23%	流通股本1,008万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LTRN","market":"US","secType":"STK","nameCN":"Lantern Pharma Inc.","latestPrice":3.38,"timestamp":1779825600000,"preClose":3.5,"halted":0,"volume":224585,"hourTrading":{"tag":"盘后","latestPrice":3.306,"preClose":3.38,"latestTime":"19:03 EDT","volume":3623,"amount":11982.3948,"timestamp":1779836625244,"change":-0.074,"changeRate":-0.021893,"amplitude":0.023669},"delay":0,"changeRate":-0.034285714285714315,"floatShares":10083000,"shares":12758872,"eps":-1.449423,"marketStatus":"未开盘","change":-0.12,"latestTime":"05-26 16:00:00 EDT","open":3.53,"high":3.7,"low":3.34,"amount":788520.764771,"amplitude":0.102857,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.449423,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779868800000},"marketStatusCode":0,"adr":0,"listingDate":1591848000000,"exchange":"NASDAQ","adjPreClose":3.5,"preHourTrading":{"tag":"盘前","latestPrice":3.548,"preClose":3.5,"latestTime":"07:59 EDT","volume":23,"amount":79.0198051,"timestamp":1779796779480,"change":0.048,"changeRate":0.013714,"amplitude":0.034914},"postHourTrading":{"tag":"盘后","latestPrice":3.306,"preClose":3.38,"latestTime":"19:03 EDT","volume":3623,"amount":11982.3948,"timestamp":1779836625244,"change":-0.074,"changeRate":-0.021893,"amplitude":0.023669},"volumeRatio":0.72836,"impliedVol":1.4606,"impliedVolPercentile":0.7371},"requestUrl":"/m/hq/s/LTRN","defaultTab":"news","newsList":[{"id":"1192417150","title":"Lantern Pharma宣布针对Lp-300在非吸烟NSCLC患者中的Harmonic™二期试验FDA C类会议请求取得圆满成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1192417150","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192417150?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:33","pubTimestamp":1779190389,"startTime":"0","endTime":"0","summary":"Lantern Pharma公司宣布，其针对旗下药物Lp-300在非吸烟非小细胞肺癌（NSCLC）患者中进行的Harmonic™二期临床试验，向美国食品药品监督管理局（FDA）提交的C类会议请求已获得成功结果。这一积极进展标志着该试验方案与监管路径获得了关键性的初步认可，为后续临床开发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136842954","title":"Lantern Pharma Inc. 宣布Harmoni试验将终止对照组，转为单臂设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1136842954","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136842954?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:32","pubTimestamp":1779190366,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. 宣布，其正在进行的Harmoni试验将终止对照组，并转为单臂设计。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151979103","title":"Lantern Pharma Inc. 宣布与现有股东及一家机构投资者进行最高925万美元的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1151979103","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151979103?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:01","pubTimestamp":1778673717,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. 宣布，公司已与现有股东及一家机构投资者达成协议，将进行一项最高价值达925万美元的注册直接发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191406065","title":"Lantern Pharma Inc. 旗下LP-300展现8.3个月中位无进展生存期 且无额外毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1191406065","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191406065?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:09","pubTimestamp":1776686962,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. 近日宣布，其研发的药物LP-300在临床试验中取得积极成果。数据显示，接受LP-300治疗的患者群体，其中位无进展生存期达到8.3个月。尤为关键的是，该治疗方案并未引入额外的毒性反应，显示出良好的安全性特征。这一结果标志着LP-300在特定患者群体中的治疗潜力，为后续的临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123261151","title":"Lantern Pharma将以最大努力基础发行普通股；规模未披露 - 美国证监会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1123261151","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123261151?lang=zh_cn&edition=full","pubTime":"2026-03-31 06:02","pubTimestamp":1774908132,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc.宣布，计划以最大努力基础发行普通股。根据提交给美国证券交易委员会的文件，此次发行的具体规模尚未披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179740153","title":"Lantern Pharma公布2025年第四季度及全年财务业绩并披露业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1179740153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179740153?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:06","pubTimestamp":1774901196,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc.近日发布2025财年第四季度及全年财务报告，同步更新公司核心业务发展动态。通过人工智能驱动的新型药物开发模式，企业正加速推进多项肿瘤靶向疗法的临床研究。最新财报显示，其研发管线取得突破性进展，现金流管理策略持续优化，为长期价值创造奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194911201","title":"Lantern Pharma Inc. 拟采取一切法律手段，并考虑将此事提交相关监管机构","url":"https://stock-news.laohu8.com/highlight/detail?id=1194911201","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194911201?lang=zh_cn&edition=full","pubTime":"2026-03-28 07:25","pubTimestamp":1774653919,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. 宣布，公司计划寻求所有可行的法律救济途径，并正考虑将相关事项提交给适当的监管机构处理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135628328","title":"Lantern Pharma 确认 Panna Sharma 继续担任总裁兼CEO，并提醒投资者警惕虚假第三方报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1135628328","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135628328?lang=zh_cn&edition=full","pubTime":"2026-03-28 07:24","pubTimestamp":1774653853,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc.（简称：Lantern Pharma）已正式确认，Panna Sharma 目前仍担任公司总裁兼首席执行官职务，并未发生人事变动。与此同时，公司特别向投资者发出警示，指出近期存在一份来源不明的第三方报告，其内容包含不实信息，可能对市场造成误导。Lantern Pharma 强调，该报告未经公司授权或认可，建议投资者以公司官方发布的信息为准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191663368","title":"Lantern Pharma获FDA批准启动儿童脑癌治疗研究，盘前股价大涨11.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191663368","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191663368?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:20","pubTimestamp":1774614030,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. (LTRN) 股价在盘前交易中飙升11.5%，此前该公司宣布已获得美国食品药品监督管理局（FDA）的许可，将启动一项针对儿童脑癌的治疗研究。这一关键监管绿灯为该公司推进其创新疗法扫清了道路，标志着其在肿瘤治疗领域的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151537547","title":"Lantern Pharma与Starlight Therapeutics宣布Star-001儿科中枢神经系统癌症一期试验获FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1151537547","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151537547?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:30","pubTimestamp":1774611033,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc.（简称：Lantern Pharma）与Starlight Therapeutics共同宣布，其候选药物Star-001已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准，将启动针对儿科中枢神经系统（CNS）癌症的一期临床试验。此次批准标志着该药物在儿童脑肿瘤治疗领域的临床开发迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139134751","title":"Lantern Pharma Inc. 启动评估Star-001单药及与螺内酯联用治疗儿童中枢神经系统癌症的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139134751","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139134751?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:30","pubTimestamp":1774611030,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. 宣布启动一项新的临床试验，旨在评估其候选药物Star-001作为单一疗法以及与螺内酯联合用药在治疗儿童中枢神经系统（CNS）癌症中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169885914","title":"Lantern Pharma Inc. 计划与Poetic联盟合作，在美国、加拿大和以色列的14家癌症中心开展试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1169885914","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169885914?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:30","pubTimestamp":1774611029,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc. 近期宣布，将与Poetic联盟携手，计划在美国、加拿大及以色列的14家顶尖癌症中心推进一项重要临床试验。此次合作旨在探索创新疗法在多种癌症治疗中的应用潜力，进一步拓展公司的研发版图与国际影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612129803","title":"Lantern Pharma Inc.盘中异动 股价大跌5.50%报2.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612129803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612129803?lang=zh_cn&edition=full","pubTime":"2026-02-20 01:27","pubTimestamp":1771522057,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日01时27分，Lantern Pharma Inc.股票出现波动，股价急速下挫5.50%。Lantern Pharma Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Dermata Therapeutics, Inc.、Briacell Therapeutics Corp C/Wts 、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Enveric Biosciences, Inc.、Pmgc Holdings Inc.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为1215.88%、785.85%、740.44%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Dermata Therapeutics, Inc.，振幅分别为247.75%、51.67%、43.62%。Lantern Pharma Inc.公司简介：Lantern Pharma Inc是一家人工智能公司，致力于改变肿瘤药物发现和开发的成本、速度和时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220012737a4b3f38e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220012737a4b3f38e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610697232","title":"Lantern Pharma Inc.盘中异动 股价大涨5.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610697232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610697232?lang=zh_cn&edition=full","pubTime":"2026-02-10 02:33","pubTimestamp":1770661990,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日02时33分，Lantern Pharma Inc.股票出现波动，股价急速拉升5.81%。Lantern Pharma Inc.股票所在的生物技术行业中，整体跌幅为0.57%。其相关个股中，Humacyte Inc C/Wts 27/08/2026 、Moolec Science Sa C/Wts 30/01/2028、Humacyte, Inc.涨幅较大，Agomab Therapeutics Nv、Liminatus Pharma, Inc.、Aim Immunotech Inc.较为活跃，换手率分别为372.18%、222.85%、30.24%，振幅较大的相关个股有Liminatus Pharma, Inc.、Moolec Science Sa C/Wts 30/01/2028、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为77.17%、59.15%、52.99%。Lantern Pharma Inc.公司简介：Lantern Pharma Inc是一家人工智能公司，致力于改变肿瘤药物发现和开发的成本、速度和时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021002331097a58733&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021002331097a58733&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147964916","title":"Lantern Pharma Inc.：临床试验达到所有主要安全性和耐受性终点，并确立明确的推荐二期剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1147964916","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147964916?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:42","pubTimestamp":1764769338,"startTime":"0","endTime":"0","summary":"Lantern Pharma Inc.：临床试验达到所有主要安全性和耐受性终点，并确立明确的推荐二期剂量","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112567254","title":"Lantern Pharma发布Lp-184一期a阶段的积极结果，显示在重度治疗的晚期癌症患者中具备持久的疾病控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1112567254","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112567254?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:37","pubTimestamp":1764769035,"startTime":"0","endTime":"0","summary":"Lantern Pharma发布Lp-184一期a阶段的积极结果，显示在重度治疗的晚期癌症患者中具备持久的疾病控制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518789671","title":"Lantern Pharma Inc.盘中异动 下午盘股价大跌5.46%报3.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518789671?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:09","pubTimestamp":1741633784,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日03时09分，Lantern Pharma Inc.股票出现波动，股价急速下跌5.46%。Lantern Pharma Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为6241.48%、3860.05%、1021.55%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Lantern Pharma Inc.公司简介：Lantern Pharma Inc是一家人工智能公司，致力于改变肿瘤药物发现和开发的成本、速度和时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311030944abf37882&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311030944abf37882&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516776966","title":"Lantern Pharma Inc.盘中异动 股价大跌5.39%报3.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516776966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516776966?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:41","pubTimestamp":1741099305,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时41分，Lantern Pharma Inc.股票出现波动，股价急速下挫5.39%。Lantern Pharma Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Capricor Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1118.41%、1103.36%、453.16%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为37.67%、22.25%、21.85%。Lantern Pharma Inc.公司简介：Lantern Pharma Inc是一家人工智能公司，致力于改变肿瘤药物发现和开发的成本、速度和时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224145963947cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224145963947cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516666881","title":"Lantern Pharma Inc.盘中异动 下午盘急速下跌6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516666881?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:47","pubTimestamp":1741031249,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时47分，Lantern Pharma Inc.股票出现波动，股价大幅下挫6.08%。Lantern Pharma Inc.股票所在的生物技术行业中，整体涨幅为0.70%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4562.65%、208.37%、182.02%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Lantern Pharma Inc.公司简介：Lantern Pharma Inc是一家人工智能公司，致力于改变肿瘤药物发现和开发的成本、速度和时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304034729989a555e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304034729989a555e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514685907","title":"Lantern Pharma Inc.盘中异动 股价大涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514685907","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514685907?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:04","pubTimestamp":1740582244,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时04分，Lantern Pharma Inc.股票出现异动，股价快速上涨5.52%。Lantern Pharma Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为4662.53%、160.40%、143.18%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.，振幅分别为155.93%、39.47%、29.31%。Lantern Pharma Inc.公司简介：Lantern Pharma Inc是一家人工智能公司，致力于改变肿瘤药物发现和开发的成本、速度和时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262304059893b13e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262304059893b13e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LTRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lanternpharma.com","stockEarnings":[{"period":"1week","weight":0.0939},{"period":"1month","weight":0.374},{"period":"3month","weight":0.1777},{"period":"6month","weight":-0.1105},{"period":"1year","weight":0.0274},{"period":"ytd","weight":0.1155}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lantern Pharma Inc.成立于2013年11月7日。该公司是一家临床阶段生物技术公司，致力于利用人工智能（“A.I.”），机器学习和基因组数据来简化药物开发流程并使将要治疗的患者能从其靶向肿瘤治疗中受益。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.031352},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.024402},{"month":3,"riseRate":0.5,"avgChangeRate":0.045479},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.042374},{"month":5,"riseRate":0.666667,"avgChangeRate":0.124587},{"month":6,"riseRate":0.4,"avgChangeRate":-0.03205},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.020452},{"month":8,"riseRate":0.5,"avgChangeRate":0.052764},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.071519},{"month":10,"riseRate":0,"avgChangeRate":-0.151349},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098056},{"month":12,"riseRate":0.5,"avgChangeRate":0.047826}],"exchange":"NASDAQ","name":"Lantern Pharma Inc.","nameEN":"Lantern Pharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lantern Pharma Inc.(LTRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lantern Pharma Inc.(LTRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lantern Pharma Inc.,LTRN,Lantern Pharma Inc.股票,Lantern Pharma Inc.股票老虎,Lantern Pharma Inc.股票老虎国际,Lantern Pharma Inc.行情,Lantern Pharma Inc.股票行情,Lantern Pharma Inc.股价,Lantern Pharma Inc.股市,Lantern Pharma Inc.股票价格,Lantern Pharma Inc.股票交易,Lantern Pharma Inc.股票购买,Lantern Pharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lantern Pharma Inc.(LTRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lantern Pharma Inc.(LTRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}